Home » Business News » 2012 » December » December 10, 2012

Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer

December 10, 2012 - Lund, Sweden And Paris

Active Biotech (NASDAQ OMXNORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced thatthePhase III clinical trial for tasquinimod, a novel compound for thetreatment ofprostate cancer, is successfully enrolled with over 1,200 randomizedpatients asplanned in the clinical protocol. This achievement triggers a EUR10 millionmilestone payment from Ipsen to Active Biotech.

This study is a global, pivotal, randomized,double-blind, placebo-controlled Phase III clinical trial of tasquinimod inpatients with metastatic castrateresistant prostate cancer (mCRPC). The aim of the study is to confirmtasquinimod's efficacy, with radiological Progression Free Survival (PFS)asprimary endpoint and overall survival (OS) as secondary endpoint. The studyrecruited patients in more than 250 centers all over the word.

Marc de Garidel, Chairman and Chief Executive Officer of Ipsen, said:"The on-schedule recruitment of tasquinimod phase III clinical trialhighlights Active Biotech's commitment and the growing interest from themedical community for an innovative and differentiated mode of action."Marc de Garidel added: "We nowlook forward to confirming the encouraging phase II results and bringing anewtreatment option to patients with mCRPC."

"I am very satisfied by the speed of recruitment of prostate cancerpatientsinto this study. We now look forward to the continued development of thisglobaltrial and the subsequent development of this unique drug also in otherindications", said Tomas Leanderson, President & CEO Active Biotech.

About tasquinimod

Tasquinimod has a pleiotropic mode of action which includesimmunomodulatory,anti-angiogenic and anti-metastatic activity. Today the development oftasquinimod is principally focused on the treatment of prostate cancer.It was announced in December 2009 that the primary endpoint of the Phase IIclinical study, to show a higher fraction of patients with no diseaseprogression during the six-month period of treatment using tasquinimod, hadbeenmet. Phase II results were published in Journal of Clinical Oncology inSeptember 2011. The results showed that 6 month progression-freeproportions forTASQ and placebo groups were 69% and 37%, respectively (p<.0001). Themedianprogression free survival was 7.6 months for the tasquinimod group,compared to3.3 months for the placebo group (p=0.0042).Analysis of up to three years safety data from the Phase II study,presented atthe EAU February 2012, show that treatment side effects were mild tomoderate (~5% of AEs grade 3-4), manageable and less frequent after two months oftherapy.The adverse events observed included gastrointestinal disorders, primarilyobserved initially during treatment, fatigue and musculoskeletal pain.In June, 2012, overall survival (OS) data was presented at ASCO (AmericanSociety of Clinical Oncology).In October, 2012, biomarker data were presented at the scientific congressESMO(European Society for Medical Oncology). The results support an effect oftasquinimod on both immunomodulation and angiogenesis positioningtasquinimod asa potentially unique therapeutic approach with a mechanism of action thatdoesnot target the androgen receptor pathway.Also, in October 2012, the independent Data and Safety Monitoring Board(DSMBmonitoring the ongoing Phase III trial, recommended that the studycontinues inaccordance with the protocol since no safety-related issues were noted.A new Phase II, proof-of-concept clinical trial was initiated and whichaims atestablishing the clinical efficacy of tasquinimod used as maintenancetherapy inpatients with mCRPC who have not progressed after a first-line docetaxelbasedchemotherapy.Ipsen has also initiated an innovative Phase II proof-of-concept clinicaltrialwith tasquinimod, to evaluate the safety and efficacy of tasquinimod inadvancedor metastatic hepato-cellular, ovarian, renal cell and gastric carcinomasinpatients who have progressed after standard therapies.

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company withfocus on autoimmune/inflammatory diseases and cancer. Projects in pivotalphaseare laquinimod, an orally administered small molecule with uniqueimmunomodulatory properties for the treatment of multiple sclerosis, TASQforprostate cancer and ANYARA primarily for the treatment of renal cellcancer. Inaddition, laquinimod is in Phase II development for Crohn's and Lupus. Thecompany also has one additional project in clinical development, the orallyadministered compound 57-57 for Systemic Sclerosis. Please for more information.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total salesexceeding EUR1.1 billion in 2011. Ipsen's ambition is to become a leader inspecialty healthcare solutions for targeted debilitating diseases. Itsdevelopment strategy is supported by four franchises: neurology /Dysport®,endocrinology / Somatuline®, uro-oncology / Decapeptyl® andhemophilia.Moreover, the Group has an active policy of partnerships. Ipsen's R&D isfocusedon its innovative and differentiated technological platforms, peptides andtoxins. In 2011, R&D expenditure totaled more than EUR250 million, above21% ofGroup sales. The Group has total worldwide staff of close to 4,500employees.Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN,ISINcode: FR0010259150) and eligible to the "Service de RèglementDifféré" ("SRD").The Group is part of the SBF 120 index. Ipsen has implemented a SponsoredLevelI American Depositary Receipt (ADR) program, which trade onthe over-the-counter market in the United States under the symbol IPSEY.For more information onIpsen, visit

Ipsen Forward Looking Statement

The forward-looking statements, objectives and targets contained herein arebased on the Group's management strategy, current views and assumptions.Suchstatements involve known and unknown risks and uncertainties that may causeactual results, performance or events to differ materially from thoseanticipated herein. All of the above risks could affect the Group's futureability to achieve its financial targets, which were set assumingreasonablemacroeconomic conditions based on the information available today.Moreover, the targets described in this document were prepared withouttakinginto account external growth assumptions and potential future acquisitions,which may alter these parameters. These objectives are based on data andassumptions regarded as reasonable by the Group. These targets depend onconditions or facts likely to happen in the future, and not exclusively onhistorical data. Actual results may depart significantly from these targetsgiven the occurrence of certain risks and uncertainties, notably the factthat apromising product in early development phase or clinical trial may end upneverbeing launched on the market or reaching its commercial targets, notablyforregulatory or competition reasons. The Group must face or might facecompetitionfrom Generics that might translate into a loss of market share.Furthermore, the Research and Development process involves several stageseachof which involves the substantial risk that the Group may fail to achieveitsobjectives and be forced to abandon its efforts with regards to a productinwhich it has invested significant sums. Therefore, the Group cannot becertainthat favorable results obtained during pre-clinical trials will beconfirmedsubsequently during clinical trials, or that the results of clinical trialswillbe sufficient to demonstrate the safe and effective nature of the productconcerned. The Group also depends on third parties to develop and marketsome ofits products which could potentially generate substantial royalties; thesepartners could behave in such ways which could cause damage to the Group'sactivities and financial results. The Group cannot be certain that itspartnerswill fulfill their obligations. It might be unable to obtain any benefitfromthose agreements. A default by any of the Group's partners could generatelowerrevenues than expected. Such situations could have a negative impact on theGroup's business, financial position or performance.The Group expressly disclaims any obligation or undertaking to update orreviseany forward looking statements, targets or estimates contained in thispressrelease to reflect any change in events, conditions, assumptions orcircumstances on which any such statements are based, unless so required byapplicable law.The Group's business is subject to the risk factors outlined in itsregistrationdocuments filed with the French Autorité des Marchés Financiers.

Active Biotech is obligated to publish the information contained in thispressrelease in accordance with the Swedish Securities Market Act. Thisinformationwas provided to the media for publication 07:30 a.m. CET on December 10,2012.

Active Biotech and Ipsen announce completion of recruitment:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE


For further information:

Active Biotech
Tomas Leanderson
President & CEO
Tel: +46 46 19 20 95
Email Contact

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Didier Veron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: Email Contact

Financial Community
Pierre Kemula
Vice President, Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
E-mail: Email Contact

Stephane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
E-mail: Email Contact


Comment on this story